Prediction of the survival of patients with advanced ovarian cancer according to a risk model based on a scoring system

European Journal of Gynaecological Oncology

Volumn 19, Issue 6, 1998, Pages 547-552

  Schneider, D ^a   Halperin, R ^a,c   Halperin, D ^b   Bukovsky, I ^a   Hadas, E ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Ovarian carcinoma; Prognosis; Risk model; Scoring system; Survival

Indexed keywords

CA 125 ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MODEL; OVARY CARCINOMA; PARITY; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGE FACTORS; AGED; CARCINOMA; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 0032417475     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boring C. C., Squires T. S., Tong T.: "Cancer statistics 1993". CA Cancer J. Clin., 1993, 43, 1.
2. Puls L. E., Duniho T., Hunter J. E., Kryscio R., Blackhurst D., Gallion H.: "The prognostic implication of ascites in advanced-stage ovarian cancer". Gynecol. Oncol., 1996, 61, 109.
3. Yancik R.: "Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality". Cancer, 1993, 71, 517.
4. van Howelingen J. C., ten Bokkel Huinink W. W., van der Burg A. T., van Oosteram, Neijt J. P.: "Predictability of the survival of patients with advanced ovarian cancer". J. Clin. Oncol., 1989, 7, 769.
5. Omura G. A., Brady M. F., Homesley H. D., Yordan E., Major F. J., Buchsbaum H. J. et al.: "Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The gynecologic oncology group experience". J. Clin. Oncol., 1991, 9, 1138.
6. Warwick J., Kehoe S., Earl H., Luesley D., Redman C., Chan K. K.: "Long-term follow-up of patients with advanced ovarian cancer treated in randomized clinical trials". Br. J. Cancer, 1995, 72, 1513.
7. Hunter R. W., Alexander N. D. E., Soutter W. P.: "Meta-analysis of surgery in advanced ovarian carcinoma. Is maximum cytoreductive surgery an independent determinant of prognosis?". Am. J. Obstet. Gynecol., 1992, 166, 504.
8. Pettersson F.: "Annual report on the results of treatment in gynecological cancer". FIGO 1994. Volume 22. Stockholm, Sweden 1994, 93.
9. Serov S. F., Scully R. E., Sobin L. H.: "Histological typing of ovarian tumors". In: "International histological classification of tumors". Geneva, World Health Organization, 1973, 17.
10. Russell P., Bannatyne P.: "Surgical pathology of the ovaries". New York, Churchill Livingstone, 1989, 190.
11. Kaplan E. L., Meier P.: "Nonparametric estimation for incomplete observations". J. Am. Stat. Assoc., 1958, 53, 457.
12. Frasci G., Conforti S., Zullo F., Mastrantonio P., Comella G., Comella P. et al.: "A risk model for ovarian carcinoma patients using CA 125". Cancer, 1996, 77, 1122.
13. Mogensen O.: "Prognostic value of CA 125 in advanced ovarian cancer. Gynecol. Oncol., 1992, 44, 207.
14. Michel G., De Iaco P., Castaigne D., El-Hassan M. J., Lobreglio R., Lhommé C. et al.: "Extensive cytoreductive surgery in advanced ovarian carcinoma". Eur. J. Gynaecol. Oncol., 1997, 18, 9.
15. Lund B., Williamson P., van Houwelingen H. C., Neijt J. P.: "Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma". Cancer Res., 1990, 50, 4626.
16. Massi D., Susini T., Savino L., Boddi V., Amunni G., Colafranceschi M.: "Epithelial ovarian tumors in the reproductive age group". Cancer, 1996, 77, 1131.
17. Zanetta G., Keeney G. L., Cha S. S., Wieand H. S., Katzmann J. A., Podratz K. C.: "DNA index by flow cytometric analysis: An additional prognostic factor in advanced ovarian carcinoma without residual disease after primary operation". Gynecol. Oncol., 1996, 62, 208.
18. Aure J. C., Hoes K., Kolstad P.: "Clinical and histological studies of ovarian carcinoma". Obstet. Gynecol., 1971, 37, 1.
19. Fathalla M. F.: "Incessant ovulation - a factor in ovarian neoplasia?". Lancet, 1971, 2, 163.
20. Cervantes A.: "Prognostic factors in advanced ovarian cancer". Int. J. Gynecol. Cancer, 7 suppl. 1997, 1, 4.
21. Bertelsen K., Holund B., Andersen E.: "Reproducibility and prognostic value of histologic type and grade in early epithelial ovarian cancer". Int. J. Gynecol. Cancer, 1993, 3, 72.
22. Kallioniemi O. P., Punnonen R., Mattila J., Lehtinen M., Koivula T.: "Prognostic significance of DNA index, multiploidy and S-phase fraction in ovarian cancer". Cancer, 1988, 67, 334.
23. Friedlander M. L., Hedley D. W., Swanson C., Russell P.: "Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer". J. Clin. Oncol., 1988, 6, 282.
24. Chalas E., Welshinger M., Engellener W., Chumas J., Barbieri R., Mann W. J.: "The clinical significance of thrombocytosis in women presenting with a pelvic mass". Am. J. Obstet. Gynecol., 1992, 166, 974.
25. Watson J. M., Sensintaffar J. L., Berck J. S., Martinez-Maza O.: "Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures". Cancer Res., 1990, 50, 6959.
26. Imai T., Koike K., Kubo T., Kikuchi T., Amano Y., Takagi M. et al.: "Interleukin -6 supports human megakaryocyte proliferation and differentiation in vitro". Blood, 1991, 78, 1969.
27. Xu F. J., Ramakrishnan S., Daly L., Soper J. T., Berchuck A., Clarke-Pearson D., Bast R. C. Jr.: "Increased serum levels of macrophage colony-stimulating factor in ovarian cancer". Am. J. Obstet. Gynecol., 1991, 165, 1356.
28. Zeimet A. G., Marth C., Muller-Holzner E., Daxenbichler G., Dapunt O.: "Significance of thrombocytosis in patients with epithelial ovarian cancer". Am. J. Obstet. Gynecol., 1994, 170, 549.
29. Awais G. M.: "Serum lactic dehydrogenase levels in the diacnosis and treatment of carcinoma of the ovary". Am. J. Obstet. Gynecol., 1973, 116, 1053.
30. Kukuchi Y., Hisano A., Kuki E., Hirata J., Nagata I.: "Total lactate dehydrogenase and its isozymes in serum from patients with primary carcinoma of the ovary". Gynecol. Obstet. Invest., 1991, 31, 161.
31. Rustin G. J., Gennings J. N., Nelstrop A. E., Covarrubias H., Lambert H. E., Bagshawe K. D.: "Use of CA 125 to predict survival of patients with ovarian carcinoma". J. Clin. Oncol., 1989, 7, 1667.
32. Mogensen O.: "Prognostic value of CA 125 in advanced ovarian cancer". Gynecol. Oncol., 1992, 44, 207.
33. Geisler J. P., Miller G. A., Lee T. H., Harwood R. M., Wiemann M. C., Geisler H. E.: "Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma". J. Reprod. Med., 1996, 41, 140.
34. Schneider D., Halperin R., Lange R., Bukovsky I., Herman A.: "Peritoneal fluid laclate dehydrogenase in ovarian cancer". Gynecol. Oncol., 1997, 66, 399.